Temozolomide
View article: Supplementary Figure 1 from Current Status and Challenges of Vaccination Therapy for Glioblastoma
Supplementary Figure 1 from Current Status and Challenges of Vaccination Therapy for Glioblastoma Open
Current status and challenges of vaccination therapy for glioblastoma.
View article: Supplementary Figures and Legends, Supplementary Tables from Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis
Supplementary Figures and Legends, Supplementary Tables from Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis Open
S1. BASP1 downregulation is associated with poor prognosis in glioma patients.S2. Low expression of BASP1 is associated with poor prognosis in CGGA dataset.S3. Dysregulation of BASP1 alters chemoresistance of glioma cells to TMZ treatment …
View article: Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM)
Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM) Open
Glioblastoma (GBM) remains the most aggressive primary brain tumor, characterized by extensive intra-tumoral heterogeneity, profound local immunosuppression, and a highly adaptive tumor microenvironment that resists conventional therapies.…
View article: Surgical Outcomes of Glioblastoma in a Low-Resource Environment
Surgical Outcomes of Glioblastoma in a Low-Resource Environment Open
View article: 6-Gingerol enhances the anti-tumor activity of temozolomide by inhibiting EGR1/GDF15 signaling in glioblastoma
6-Gingerol enhances the anti-tumor activity of temozolomide by inhibiting EGR1/GDF15 signaling in glioblastoma Open
View article: Supplementary Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Supplementary Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma Open
supplementary figures & legends
View article: Supplemental Figure S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Supplemental Figure S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma Open
Progression Free Survival by Exosome (50-120nm, N=24) Concentration Relative Change (< -0.01, >-0.01): p=0.19 [<-0.01: median=6.3, 95% CI 4.0 to 12.0, >-0.01: median=4.4 95% CI 2.3, 5.9]
View article: Supplementary Figure S2 from The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma
Supplementary Figure S2 from The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma Open
Fig. S2. TMZ+HP Hp induces ferroptosis in GBM cells.
View article: Supplementary Figure S6 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Supplementary Figure S6 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma Open
Supplementary figure 6. Wound dehiscence.
View article: Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms Open
Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (…
View article: Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms Open
Evaluation of circulating CD8+ cell subsets. (A) Changes in levels of circulating CD8+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR7-), and terminal effector memory (TE; CD45RA+ CCR7-) subsets…
View article: Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Predicted TSA/TAA-derived N-peptides and D-neopeptides
View article: Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Vaccinated D-neopeptides activate tumor-infiltrating antitumor T cells. (A) Circos plots provide an overview of the frequencies of Vβ-Jβ pairing in the primary and recurrent tumors. (B) Surface TCR β chain expression of the D-neopeptide-sp…
View article: Supplementary Data from Temozolomide Sensitizes <i>ARID1A</i>-Mutated Cancers to PARP Inhibitors
Supplementary Data from Temozolomide Sensitizes <i>ARID1A</i>-Mutated Cancers to PARP Inhibitors Open
Supplementary Figures
View article: Supplementary Table S1 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial
Supplementary Table S1 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial Open
Synopsis of Protocol
View article: PROTEOMIC PROFILING OF RAT ORTHOTOPIC GLIOBLASTOMA AND HEALTHY BRAIN FOLLOWING PROTON MINIBEAN RADIATION THERAPY
PROTEOMIC PROFILING OF RAT ORTHOTOPIC GLIOBLASTOMA AND HEALTHY BRAIN FOLLOWING PROTON MINIBEAN RADIATION THERAPY Open
View article: Supplementary Figure S5 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Supplementary Figure S5 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma Open
A. An MR image revealed a hyperintense signal in the DWI sequence, indicating an acute ischemic stroke in the right ACA region (white arrows). B. CT angiography showed poor visualization of the distal ACA.
View article: Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms Open
Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screeni…
View article: Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial Open
Supplementary Figure 1: Overview of the clinical trial and biomarker analysis. Out of 596 patients in the EORTC-26101 trial, patient tumor tissue to perform DNA methylation (Meth) and NGS sequencing analysis was available from 380 patients…
View article: Figure S1 from Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Figure S1 from Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Open
Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.
View article: EGFR-Driven Phenotypes Dictate Differential Therapeutic Response to Radiotherapy and Temozolomide in Glioblastoma.
EGFR-Driven Phenotypes Dictate Differential Therapeutic Response to Radiotherapy and Temozolomide in Glioblastoma. Open
Despite the established Stupp regimen, glioblastoma (GBM) remains a highly lethal cancer with a 5-year survival rate below 10%. The epidermal growth factor receptor (EGFR) is frequently amplified or mutated in GBM, and we have previously s…
View article: Daily locomotor activity declines with tumor growth and disease progression in glioblastoma
Daily locomotor activity declines with tumor growth and disease progression in glioblastoma Open
Glioblastoma (GBM) is an aggressive brain tumor that often progresses despite resection and treatment. Timely and continuous assessment of GBM progression is critical to expedite secondary surgery or enrollment in clinical trials. However,…
View article: Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial Open
Supplementary Figure 6: Overall Survival according to PTEN mutation status in the group of IDH-wildtype glioblastomas (n = 362).
View article: Supplementary Figure S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Supplementary Figure S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma Open
Axial, sagittal and coronal gadolinium-enhanced MRI at pre-baseline (A-C; yellow arrows), 6 months later demonstrating complete response after anlotinib plus temozolomide (E-G). Axial Fluid-Attenuated Inversion Recovery (FLAIR, D) image at…
View article: Supplementary Figure S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Supplementary Figure S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma Open
A-B. Kaplan-Meier plots of progression-free survival and overall survival (Full analysis set). The x-axes indicated times since enrollment.
View article: Supplemental Figure S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Supplemental Figure S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma Open
CONSORT flow diagram with patient disposition and treatment
View article: Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial Open
Supplementary Figure 3: Characteristics of RTK1 tumors in comparison to RTK2 and MES. A Distribution of MGMT promotor methylation in main glioblastoma methylation subgroups. Classifier assignment is based on the v12.5 version (n = 295). Mu…
View article: DOSE CALCULATION AND EFFECT PROBABILITY MODELS TO THE OPTIMISATION OF GLIOBLASTOMA TREATMENTS WITH BNCT
DOSE CALCULATION AND EFFECT PROBABILITY MODELS TO THE OPTIMISATION OF GLIOBLASTOMA TREATMENTS WITH BNCT Open
View article: Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms Open
Water plot of best response in lung NEN.
View article: Supplementary Table S2 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial
Supplementary Table S2 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial Open
Representativeness of Study Participants